Lundgren, Christine
Tutzauer, Julia
Church, Sarah E.
Stål, Olle
Ekholm, Maria
Forsare, Carina
Nordenskjöld, Bo
Fernö, Mårten
Bendahl, Pär-Ola
Rydén, Lisa
Clinical trials referenced in this document:
Documents that mention this clinical trial
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
https://doi.org/10.1186/s13058-023-01719-z
Funding for this research was provided by:
The Percy Falk Foundation
Futurum – the Academy for Health and Care, Region Jönköping County
The Swedish Cancer Society (19 0388Pj and 22 2137Pj)
The Anna and Edwin Berger Foundation (2019-2022)
Governmental Funding of Clinical Research within the Swedish National Health Service (2022-40304)
The Bertha Kamprad Foundation (FBKS-2021-11)
Lund University
Article History
Received: 28 June 2023
Accepted: 25 September 2023
First Online: 29 September 2023
Declarations
:
: Oral informed consent was obtained from all participants in the original SBII:2pre trial, which was approved by the ethical committees in Lund and Linköping, Sweden. Approval for the follow-up study and the genomic analyses was obtained (Dnr LU 2015/350, Dnr LU 2017/97). Biobank approval was obtained for all the pathology departments involved.
: Not applicable.
: The co-author, ME, has had a consultant/advisory role at Pfizer and Novartis. The co-author, SC, is an employee and shareholder of NanoString. Co-author MF has had a consultant/advisory role in Mavatar and has also contracted with PFS Genomics/Exact Sciences regarding genomic profiling and is a co-inventor of patent applications. The authors declare no conflicts of interest.